ABSTRACT
Oncological diseases are invariably a challenge for the modern world. Therefore, in recent decades, scientists have begun to look for compounds of natural origin that will be able to support or independently be used in oncological therapy. Among the antimicrobial proteins (AMPs), a promising family of peptides isolated from the immunized hemolymph of Hyalophora cecropia pupae has been distinguished. The cecropin family is not only characterized by antimicrobial and antifungal properties, but most importantly also has anticancer properties. Their antitumor potential is confirmed by in vitro studies conducted on several different cell lines, among others, prostate and breast cancer cell lines. This paper presents publications demonstrating cytolytic properties against tumour cells of members belonging to the cecropin family, as well as synthesized cecropin B with the introduced modification of its sequence and conjugated cecropin B with a modified luteinizing hormone-releasing hormone (LHRH). Moreover, three models of cecropin mechanisms of action are also described. The benefits and limitations associated with the use of these peptides in oncological therapy have also been demonstrated.
